Total Funding
53
73
Total FundingPost-IPO Equity raised
Growth Score
-15 pts
Heat Score
35 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
10218
Nuvectis Pharma is a biopharmaceutical company intended to develop novel targeted therapeutics for the treatment of cancer.
Uri Ben: Chief Financial Officer- Ron Bentsur: President and Chief Executive OfficerPast Role: XTL Biopharmaceuticals, Chief Executive Officer
About the Company
Nuvectis Pharma is a bio-pharmaceutical company intended to develop novel targeted therapeutics for the treatment of cancer.
Nuvectis is led by a management team comprised of industry veterans with broad and extensive drug development experience, and a proven track record of clinical and regulatory success. By leveraging our core competencies of
target selection, drug profiling, and clinical and regulatory execution we are building our pipeline of product candidates for development in various oncology indications.
